Clinical Trials

Have you been diagnosed with peripartum cardiomyopathy and are within 5 months of your due date? This study is evaluating the effectiveness of a medicine called bromocriptine to treat peripartum cardiomyopathy, or weakness of the heart muscle that occurs during or shortly after pregnancy. To participate in this study, you must be at least 18 years old, diagnosed with peripartum cardiomyopathy, and within 5 months of your delivery date. This study takes place in Pittsburgh, Pennsylvania.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Are you a 30- to 55-year-old smoker or non-smoker who would like to support better understanding of COPD risk factors? This study aims to find early signs of COPD in adults who have a high risk of this condition. Researchers will compare results from questionnaires, lung tests, and other tests in people who smoke and in people who do not smoke to look for factors that predict which people will develop COPD. To participate in this study, you must either currently smoke or have no history of smoking. This study takes place in multiple locations in the United States.

Have you or your child been diagnosed with cystic fibrosis, and would you like to support better diagnosis of lung infections? This study is exploring new ways to diagnose bacterial lung infections in people who have cystic fibrosis. The study will test whether analyzing a participant’s breath and sputum samples can help diagnose infections. Participants in this study must be at least 3 years old. This study is taking place in multiple locations in the United States.

Are you a woman 18 years old or older who has been diagnosed with LAM? This study is examining whether long-term treatment with medicine called sirolimus can stop lung damage in women who have LAM. This study takes place at multiple locations in the United States.

Do you or your child have symptoms of a serious lung disease but no diagnosis? This study aims to develop new ways to diagnose primary ciliary dyskinesia (PCD) and primary immune deficiency (PID), two conditions that can have similar symptoms. Researchers will combine information from genetic testing, lung imaging, and lung function tests to diagnose ant tell the difference between these two conditions. Participants in this study must be 5 to 45 years old. This study is taking place at multiple locations in the United States and in Canada.

Are you a shift worker who regularly gets 7 to 9 hours of sleep each day? This study is looking at whether shift work negatively affects overall bone health. The study will test whether resuming and maintaining a daily schedule that aligns with the environment, after a period of night shift work, can help reverse bone problems. To participate in this study, you must be 20 to 40 years old. This study takes place in Aurora, Colorado.

Are you a healthy adult who wants to join a study about less sitting? You might qualify for this research. Researchers are testing if walking breaks can improve cardiovascular health, like blood pressure and glucose (sugar) levels. To join, you must be 18 years old and have no long-term health issues or not be taking medications for blood pressure or diabetes. Participants will have to go to the study site for a 9-hour visit and walk on a treadmill during the day. The study is taking place in New York City, New York.

his trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.